ArticleGenes & development2022
Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform.
Article in Genes & development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- TET1-mediated DNA demethylation and transcription activation of MRPS17 induces lung adenocarcinoma through PI3K-AKT-mTOR pathway.Journal of molecular histology · 2026Article
- Organoid technology in cancer research.Molecular biomedicine · 2026Review
- Article
- Recapitulating lung cancer metastasisOncology reports · 2026Review
- Single-cell lineage tracing in tumor organoids identifies expansion states depicting the origin and progression of lung adenocarcinoma.Frontiers in immunology · 2026Article
- Tumor organoids for testing metabolic flexibility in precision oncology.Frontiers in oncology · 2026Review
- Immunogenic cell death and tertiary lymphoid structures jointly define dysregulated antitumor immune states and therapeutic vulnerability in lung adenocarcinoma.Frontiers in immunology · 2026Article
- Prognostic and immunological potential of AC012236.1/hsa-miR-30d-5p CeRNA of AVEN by integrated analysis of single-cell and bulk RNA-seq in lung adenocarcinoma.Scientific reports · 2025Article
- In vitro biomimetic models for respiratory diseases: progress in lung organoids and lung-on-a-chip.Stem cell research & therapy · 2025Review
- Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy.Journal of experimental & clinical cancer research : CR · 2025Article
- Hsa-miR-21 promoted the progression of lung adenocarcinoma by regulating LRIG1 expression.BMC pulmonary medicine · 2025Article
- A novel mitochondrial quality regulation gene signature for anticipating prognosis, TME, and therapeutic response in LUAD by multi-omics analysis and experimental verification.Cancer cell international · 2025Article
- Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy.Journal for immunotherapy of cancer · 2025Review
- Lung cancer organoids: a new strategy for precision medicine research.Translational lung cancer research · 2025Review
- [Prospects of Smoking Hazards Research Using Lung Organoid].Jugan geon-gang gwa jilbyeong · 2025Review
- Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing.Frontiers in pharmacology · 2025Review
- Exploration of organoids in ovarian cancer: From basic research to clinical translation.Translational oncology · 2024Review
- Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma.Cancer immunology, immunotherapy : CII · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Lung cancer is the leading cause of cancer-related death worldwide. Lung adenocarcinoma (LUAD), the most common histological subtype, accounts for 40% of all cases. While existing genetically engineered mouse models (GEMMs) recapitulate the histological progression and transcriptional evolution of human LUAD, they are time-consuming and technically demanding. In contrast, cell line transplant models are fast and flexible, but these models fail to capture the full spectrum of disease progression. Organoid technologies provide a means to create next-generation cancer models that integrate the most advantageous features of autochthonous and transplant-based systems. However, robust and faithful LUAD organoid platforms are currently lacking. Here, we describe optimized conditions to continuously expand murine alveolar type 2 (AT2) cells, a prominent cell of origin for LUAD, in organoid culture. These organoids display canonical features of AT2 cells, including marker gene expression, the presence of lamellar bodies, and an ability to differentiate into the AT1 lineage. We used this system to develop flexible and versatile immunocompetent organoid-based models of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.